Trial Profile
Glucagon-like Peptide-1 Metabolism in the Setting of Acute Neprilysin Inhibition
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Valsartan (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 03 Mar 2023 Planned End Date changed from 30 Jun 2022 to 30 Jun 2024.
- 03 Mar 2023 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2024.
- 15 Jul 2020 Planned End Date changed from 30 Jun 2020 to 30 Jun 2022.